Use of adipose tissue-derived stromal cells for chondrocyte differentiation and cartilage repair
View Patent ↗Methods and compositions for directing adipose-derived stromal cells cultivated in vitro to differentiate into cells of the chondrocyte lineage are disclosed. The invention further provides a variety of chondroinductive agents which can be used singly or in combination with other nutrient components to induce chondrogenesis in adipose-derived stromal cells either in cultivating monolayers or in a biocompatible lattice or matrix in a three-dimensional configuration. Use of the differentiated chondrocytes for the therapeutic treatment of a number of human conditions and diseases including repair of cartilage in vivo is disclosed.
1. A medium for differentiating adipose tissue derived stromal cells into chondrocyte cells, comprising:
a chemically defined culture medium having or supplemented with
(i) a chondroinductive agent capable of activating any cellular transduction pathway leading to the mature chondrocyte phenotype;
(ii) an antibiotic;
(iii) a nutrient supplement, wherein the nutrient supplement comprises 1-20% fetal bovine serum or 1-20% horse serum;
(iv) ascorbate or vitamin C analogue; and
(v) a glucocorticoid or other chemical agent capable of activating the cellular glucocorticoid receptor.
2. The medium of claim 1 , wherein the chondroinductive agent is selected individually or in combination from the group consisting of: a glucocorticoid; a member of the transforming growth factor-beta superfamily; a collagenous extracellular matrix molecule; and a vitamin A analog.
3. The medium of claim 1 , wherein said antibiotic is penicillin.
4. The medium of claim 1 , wherein said antibiotic is streptomycin.
5. The medium of claim 3 , wherein the concentration of penicillin is about 10 to about 200 units per ml.
6. The medium of claim 4 , wherein the concentration of streptomycin is about 10 to about 200 μg per ml.
7. The medium of claim 2 , wherein the glucocorticoid is hydrocortisone.
8. The medium of claim 2 , wherein said glucocorticoid is dexamethasone.
9. The medium of claim 8 , wherein the concentration of dexamethasone is about 1 to about 100 nM.
10. The medium of claim 7 , wherein the concentration of hydrocortisone is about 1 to about 100 nM.
11. The medium of claim 2 , wherein said transforming growth factor-beta superfamily member is selected from the group consisting of: bone morphogenic protein-2, bone morphogenic protein-4, TGF-beta 1, TGF-beta 2, TGF-beta 3, IGF, PDGF, EGF, aFGF, bFGF, HGF, KGF, inhibin A, and chondrogenic stimulating activity factor.
12. The medium of claim 11 , wherein the concentration of transforming growth factor-beta is about 1 to about 100 ng per ml.
13. The medium according to claim 11 , further comprising TGFβ-1 at concentrations from about 1 ng/ml to about 10 ng/ml.
14. The medium of claim 2 , wherein the collagenous extracellular matrix molecule is collagen I.
15. The medium of claim 2 , wherein the vitamin A analog is retinoic acid.
16. The medium of claim 15 , wherein the concentration of retinoic acid is about 0.1 ng per ml to about 1 μg per ml.
17. A method for differentiating adipose tissue derived stromal cells into chondrocytic cells, comprising:
a) pelleting said stromal cells by centrifuging between 50,000 to 5 million cells at 500×g for 2 to 20 minutes in sterile tubes containing a medium selected form the group consisting of Dulbecco's Modified Eagle's Medium (DMEM), alpha modified Minimal Essential Medium (αMEM), and Roswell Park Memorial Institute media 1640 (RPMI Media 1640);
b) plating said isolated stromal cells at a density of 500 to 20,000 cells/cm 2 in a differentiating medium;
c) supplementing said medium with:
(i) a chondroinductive agent capable of activating any cellular signal transduction pathway leading to the mature chondrocyte phenotype;
(ii) an antibiotic;
(iii) a nutrient supplemented with 1 to 20% fetal bovine serum or 1 to 20% horse serum;
(iv) ascorbate or vitamin C analog; and
(v) a glucocorticoid or other chemical agent capable of activating the cellular glucocorticoid receptor; and d) incubating said cells at about 31° C. to 37° C. for about 3-4 weeks in with 5% CO 2 and between 1% and 20% oxygen.
18. A method for differentiating adipose tissue derived stromal cells into chondrocytic cells, comprising:
a) suspending stromal cells at a concentration of 0.5 to 10 million cells per ml in calcium alginate or any other biocompatible lattice or matrix capable of supporting chondrogenesis in a three-dimensional configuration;
b) transferring said suspended cells to 35 mm culture dishes and plating cells at a density of 500 to 20,000 cells/cm 2 in a differentiating medium comprising a chemically defined culture medium having or supplemented with:
(i) a chondroinductive agent capable of activating any cellular transduction pathway leading to the mature chondrocyte phenotype;
(ii) an antibiotic;
(iii) a nutrient supplemented with 1 to 20% fetal bovine serum or 1 to 20% horse serum;
(iv) ascorbate or vitamin C analog; and
(v) a glucocorticoid or other chemical agent capable of activating the cellular glucocorticoid receptor; and c) incubating said cells at about 31 to 37° C. for about 3-4 weeks in an incubator with 5% CO 2 and between 1% and 20% oxygen.